findmyKOL

Douglas Krakower, MD

Basic profile

Beth Israel Deaconess Medical Center

ORCID↗NPI↗
✓ Full record
RegionBoston, MA · NortheastSpecialtyInfectious DiseaseFocusInfectious Disease
Active KOLfindmyKOL type: NationalLatest publication2025Online presenceNot yet checkedPaymentsNone reportedNIH funding2012–2025Why? →

Douglas Krakower is an Infectious Disease physician affiliated with Beth Israel Deaconess Medical Center. OpenAlex indexes 193 publications with 6,087 citations (h-index 46); ClinicalTrials.gov lists 2 registered studies matched to this name.

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
193publications

Distinct works indexed by OpenAlex, matched via ORCID.

6,087citations

Total citations across indexed works.

46h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
2clinical trials

Investigator role on registered studies.

View trials ↓
5NIH grants · 2012–2025

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

110 Francis St Ste Gb
Beth Israel Deaconess Medical Center
Boston, MA 022155563

Telephone

617-632-0760

Registry record last updated 22 May 2012.

View the NPPES registry record

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Anti-infectives

    100%
    Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor48.7%
    Tivicay76%Isentress15%Dovato9%
    Part D<11 patients
    Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor29.1%
    Descovy84%Emtricitabine16%
    Part D<11 patients

    + 4 more classes in this area

Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

5 NIH research awards on record, funded 2012–2025 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”